# Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination

> **NCT07454369** · PHASE1 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 42 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** A1: Etoricoxib / Betamethasone in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.)
- **DRUG:** A2: Etoricoxib (Arcoxia®, Laboratorios Schering-Plough, S.A. de C.V.)
- **DRUG:** A3: Betamethasone (Celestone® Pediatric, Laboratorios Schering-Plough, S.A. de C.V.)

## Key facts

- **NCT ID:** NCT07454369
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-24
- **Primary completion:** 2022-11-25
- **Final completion:** 2023-01-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454369, "Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07454369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*